Johnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remission
Johnson & Johnson study shows TREMFYA® is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's disease
Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease
Johnson & Johnson Announces Pivotal Clinical Study Results for a New Soft-Tissue Surgical Robotic System
CAPLYTA® showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysis
FDA grants Priority Review for IMAAVY® as the potential first approved treatment for people living with warm autoimmune hemolytic anemia
IMAAVY® shows over two years of sustained disease control in a broad population with generalized myasthenia gravis
Johnson & Johnson Showcases CARTO-Powered Innovation, Including Debut of CARTOSOUND SONATA, to Advance Arrhythmia Care at HRS 2026
Johnson & Johnson Announces 64th Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 3.1%
Johnson & Johnson Showcases New Clinical Data for TECNIS PureSee IOL at ASCRS 2026 Demonstrating Excellent Contrast Sensitivity and Extended Range of Vision
Finlay Minerals Ltd. engages German Mining Networks and renews engagement with Investing News Network
LAURION Retains SMARTIR Marketing Ltd. to Drive Investor Awareness Ahead of Active 2026 Exploration Program
